Stephen Davies
Founder at GEMINA LABORATORIES LTD.
Net worth: 13 120 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Greene | M | - |
Ecomine Technologies Corp.
 Ecomine Technologies Corp. Trucks/Construction/Farm MachineryProducer Manufacturing Ecomine Technologies Corp. is a Canadian mining technology company. The private company was founded by Robert Crandall Greene, Robert Crandall Greene. | 7 years |
| Alison Fielding | M | 59 | 19 years | |
| Glyn Owain Edwards | M | 68 |
Summit Therapeutics Ltd.
 Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 12 years |
| Martin Cronin | M | 59 | 3 years | |
| Bola Grace | M | - | 1 years | |
| Michael Liggett | M | - | 3 years | |
| Dame Davies | M | 73 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
Oxstem Ltd.
 Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom. | - |
| Richard Vickers | M | 48 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 21 years |
| James Mallinson | M | 63 |
Oxstem Ltd.
Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom.
University of Oxford
| 11 years |
| Martha Najib | F | - | 1 years | |
| Stuart J. M. Collinson | M | 64 |
Oxstem Ltd.
Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom. | - |
| Brian Firth | M | - | 2 years | |
| Elliot Hong | M | - | 3 years | |
| Angela Russell | F | - |
Oxstem Ltd.
Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom. | - |
| Raymond Spencer | M | - |
Oxstem Ltd.
Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom. | - |
| Brad Perkins | M | - |
Oxstem Ltd.
Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom. | - |
| Hearth Henrietta | F | - |
University of Oxford
| 3 years |
| Diana Crisp | F | - | 19 years | |
| Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 years |
| Ngaire Woods | F | 62 |
University of Oxford
| 14 years |
| Bob Duggan | M | - |
Oxstem Ltd.
Oxstem Ltd. BiotechnologyHealth Technology Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom. | - |
| Stefan Hamill | M | - | 1 years | |
| John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 years |
| Marc Feldmann | M | 79 |
University of Oxford
| 13 years |
| Li Jin | M | 53 |
University of Oxford
| 12 years |
| Simon Boddie | M | 64 |
University of Oxford
| 3 years |
| Lionel Tarassenko | M | 67 |
University of Oxford
| 27 years |
| Lai Kuen Louey | M | 64 |
University of Oxford
| 13 years |
| Hugh McNaught | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Frank Armstrong | M | 67 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 7 years |
| Steven Lee | M | 57 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 3 years |
| Rabeel Warraich | M | - |
University of Oxford
| 4 years |
| James Cust | M | - |
University of Oxford
| 7 years |
| Elwyn Davies | M | - |
University of Oxford
| 3 years |
| John Lee Allen | M | - |
University of Oxford
| 15 years |
| Qin Xie | M | 44 |
University of Oxford
| 5 years |
| denise xifara | M | - |
University of Oxford
| 9 years |
| Hong Jun Zhong | M | 53 |
University of Oxford
| 3 years |
| David Sturrock | M | - |
University of Oxford
| 6 years |
| Alessandro Guazzi | M | - |
University of Oxford
| 5 years |
| Linda Maxwell | M | 50 |
University of Oxford
| 3 years |
| Tom Joy | M | - |
University of Oxford
| 4 years |
| Kai Yu Liu | M | 39 |
University of Oxford
| 4 years |
| Marco Francescon | M | - |
University of Oxford
| 4 years |
| Kwok Fung Lam | M | 50 |
University of Oxford
| 5 years |
| Matthew Powell | M | - |
University of Oxford
| 5 years |
| Sandra Ainsua Martinez | F | - |
University of Oxford
| 5 years |
| David Wurzer | M | 65 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 4 years |
| Justin X. Wang | M | - |
University of Oxford
| 5 years |
| Peter Bilitsch | M | 49 |
University of Oxford
| 6 years |
| Joe Hepplewhite | M | - |
University of Oxford
| 5 years |
| Alex Hood | M | - |
University of Oxford
| 4 years |
| Federico Ferrari | M | - |
University of Oxford
| 4 years |
| Kieran Mahanty | M | - |
University of Oxford
| 5 years |
| de Vere Max | M | - |
University of Oxford
| 4 years |
| Meng Shi | F | 36 |
University of Oxford
| 6 years |
| James Coates | M | - |
University of Oxford
| 6 years |
| Adriana Vitagliano | F | - |
University of Oxford
| 2 years |
| Benjamin Durham | M | 42 |
University of Oxford
| 3 years |
| Simon Wolfgang Hartmut Goeller | M | 44 |
University of Oxford
| 5 years |
| Chad Frischmann | M | - |
University of Oxford
| 5 years |
| emma chandra | F | - |
University of Oxford
| 3 years |
| Inga Deakin | M | - |
University of Oxford
| 5 years |
| Sam Blake | M | - |
University of Oxford
| 5 years |
| Melissa Strange | F | 44 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Danaraj Nadarajah | M | 70 |
University of Oxford
| 4 years |
| Mark Zaleski | M | - |
University of Oxford
| 1 years |
| Barry James Price | M | 80 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 12 years |
| Raymond J. Spencer | M | - |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Richard Storer | M | 76 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 6 years |
| William Graham Richards | M | 85 | 12 years | |
| Valerie Lynne Andrews | F | 64 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 5 years |
| Andrew Richards | M | 64 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 5 years |
| Soo Chuen Tan | M | - |
University of Oxford
| 3 years |
| George Elliott | M | 71 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 5 years |
| Leopoldo Giampaolo Zambeletti | M | 55 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 5 years |
| Rayhan Davis | M | 45 |
University of Oxford
| 4 years |
| Rachel Webster | M | - |
University of Oxford
| 5 years |
| David Rokoss | M | - | 6 years | |
| David Roblin | M | 57 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | 3 years |
| David John Rawlins | M | 43 |
University of Oxford
| 3 years |
| Akhil Paul | M | 39 |
University of Oxford
| 4 years |
| Robert Porter | M | 54 | - | |
| Catherine Fraser | F | - |
University of Oxford
| 4 years |
| Philip Hodges | M | - |
University of Oxford
| 7 years |
| Bina Tejura | M | 55 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| Gao Meng | F | 43 |
University of Oxford
| 5 years |
| Jan P. Peisert | M | - |
University of Oxford
| 3 years |
| Siu Kwan Sik | M | 56 |
University of Oxford
| 1 years |
| Brennan M. Leong | M | - |
University of Oxford
| 1 years |
| Sherri Hansen | F | - |
University of Oxford
| 1 years |
| James Sullivan Smith | M | - |
University of Oxford
| 3 years |
| Thomas Robinson | M | - |
University of Oxford
| 1 years |
| William Hale | M | 66 |
University of Oxford
| 2 years |
| Justin T. Marquardt | M | - |
University of Oxford
| 1 years |
| Yang Yang Zhang | M | 44 |
University of Oxford
| 3 years |
| Murdo Armstrong | M | - |
University of Oxford
| 3 years |
| Jing Yuan Ye | M | 42 |
University of Oxford
| 1 years |
| James Thetford | M | - |
University of Oxford
| 3 years |
| Shali Zhu | F | - |
University of Oxford
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 89 | 89.00% |
| Canada | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stephen Davies
- Personal Network
